piribedil has been researched along with Arteriosclerosis Obliterans in 2 studies
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argenteri, A | 1 |
| Moia, R | 1 |
| Negri, L | 1 |
| Guagliano, G | 1 |
| Bagliani, A | 1 |
| Borri, P | 1 |
1 trial available for piribedil and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[Therapeutic acquisitions on chronic obliterating peripheral arterial diseases of the lower limbs].
Topics: Arteriosclerosis Obliterans; Chronic Disease; Clinical Trials as Topic; Humans; Leg; Piribedil; Thro | 1976 |
1 other study available for piribedil and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[Piribedil (TF 871) in the treatment of arteriopathies of the lower extremities].
Topics: Adult; Aged; Arteriosclerosis Obliterans; Chronic Disease; Drug Evaluation; Drug Tolerance; Female; | 1979 |